Tezepelumab (Genetical Recombination) Subcutaneous Injection 210mg (Tezspire® / テゼスパイア皮下注210mgシリンジ)

JPY ¥230,000

Japanese Human Anti-TSLP Monoclonal Antibody (Tezepelumab (Genetical Recombination) 210mg/1.91mL). Subcutaneous injection for bronchial asthma and chronic rhinosinusitis with nasal polyps. 1.91mL [1 kit (prefilled syringe with 27G needle x 1)]. Mfd. by AstraZeneca K.K., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥211,600
10 - 19 12% JPY ¥202,400
20 + 18% JPY ¥188,600
SKU: TEZ-210-INJ Category:

Description

Product Overview / 商品概要

Tezspire Subcutaneous Injection 210mg Syringe (テゼスパイア皮下注210mgシリンジ)
Generic: Tezepelumab (Genetical Recombination) / テゼペルマブ(遺伝子組換え)
Therapeutic Category: Human Anti-TSLP Monoclonal Antibody / ヒト抗TSLPモノクローナル抗体
Manufactured by: AstraZeneca K.K. / アストラゼネカ株式会社

Composition & Specification / 組成・規格

Active Ingredient: Tezepelumab (Genetical Recombination) 210mg per 1 syringe (1.91mL) / 1シリンジ(1.91mL)中 テゼペルマブ(遺伝子組換え)210mg
Additives: L-Proline 48mg, Polysorbate 80 0.19mg, pH adjuster per 1 syringe (1.91mL) / 1シリンジ(1.91mL)中 L-プロリン 48mg、ポリソルベート80 0.19mg、pH調節剤
Appearance: Colorless to pale yellow, clear to opalescent solution. pH 4.9–5.5, osmolality ratio approximately 1 (relative to physiological saline)
外観: 無色~淡黄色の澄明~乳白光を呈する液である。pH 4.9~5.5、浸透圧比 約1(生理食塩液に対する比)

Indications / 効能効果

EN: Bronchial asthma (limited to patients with severe or refractory disease whose symptoms cannot be controlled with existing treatments); Chronic rhinosinusitis with nasal polyps (limited to patients with inadequate response to existing treatments)
JA: 気管支喘息(既存治療によっても喘息症状をコントロールできない重症又は難治の患者に限る)、鼻茸を伴う慢性副鼻腔炎(既存治療で効果不十分な患者に限る)

Dosage and Administration / 用法用量

EN: The usual dose for adults and pediatric patients aged 12 years and older is 210mg of tezepelumab (genetical recombination) administered subcutaneously once every 4 weeks. The usual dose for adults is 210mg of tezepelumab (genetical recombination) administered subcutaneously once every 4 weeks.
JA: 〈気管支喘息〉通常、成人及び12歳以上の小児にはテゼペルマブ(遺伝子組換え)として1回210mgを4週間隔で皮下に注射する。〈鼻茸を伴う慢性副鼻腔炎〉通常、成人にはテゼペルマブ(遺伝子組換え)として1回210mgを4週間隔で皮下に注射する。

Contraindications / 禁忌

EN: Patients with a history of hypersensitivity to any component of this product
JA: 本剤の成分に対し過敏症の既往歴のある患者

Regulatory Information / 規制情報

Approval No.: 30400AMX00402
Sales Started: November 2022 / 2022年11月
Classification Code: 87229
Storage: Store at 2–8°C / 2~8℃で保存
Shelf Life: 36 months / 36箇月

Packaging / 包装

Main Package (for sale): 1.91mL [1 kit (prefilled syringe with 27G needle x 1)] / 1.91mL[1キット(注射針(27G)付きプレフィルドシリンジ×1)]
Other Available Packages (by special order): 1.91mL [1 kit (prefilled syringe with 27G needle x 1)]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Tezepelumab (Genetical Recombination) Subcutaneous Injection 210mg (Tezspire® / テゼスパイア皮下注210mgシリンジ)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Tezepelumab (Genetical Recombination) Subcutaneous Injection 210mg (Tezspire®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.